These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932 [TBL] [Abstract][Full Text] [Related]
5. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma. Zhang N; Wei L; Ye M; Kang C; You H Front Immunol; 2020; 11():592612. PubMed ID: 33329578 [TBL] [Abstract][Full Text] [Related]
6. Immune-checkpoint inhibitors for glioblastoma: what have we learned? Omuro A Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):266-269. PubMed ID: 35976319 [TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy strategies for glioblastoma. Chan HY; Choi J; Jackson C; Lim M J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705 [TBL] [Abstract][Full Text] [Related]
8. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines. Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032 [TBL] [Abstract][Full Text] [Related]
9. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements. Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718 [TBL] [Abstract][Full Text] [Related]
10. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy. Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP Front Immunol; 2024; 15():1326757. PubMed ID: 38390330 [TBL] [Abstract][Full Text] [Related]
12. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. Carter TC; Medina-Flores R; Lawler BE Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753 [TBL] [Abstract][Full Text] [Related]
13. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507 [TBL] [Abstract][Full Text] [Related]
14. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042 [TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches. Wu S; Calero-Pérez P; Arús C; Candiota AP Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585 [TBL] [Abstract][Full Text] [Related]
16. Management of glioblastoma: State of the art and future directions. Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924 [TBL] [Abstract][Full Text] [Related]
17. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Neagu MR; Reardon DA Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859 [TBL] [Abstract][Full Text] [Related]
18. The N Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G Front Immunol; 2021; 12():653711. PubMed ID: 34354698 [TBL] [Abstract][Full Text] [Related]
19. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. Sanders S; Debinski W Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096 [TBL] [Abstract][Full Text] [Related]
20. Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma. Meng L; Wang C; Lu Y; Sheng G; Yang L; Wu Z; Xu H; Han C; Lu Y; Han F ACS Appl Mater Interfaces; 2021 Mar; 13(10):11657-11671. PubMed ID: 33684289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]